静脉注射克洛纳泽对儿科状态的疗效
Maxime Colmard1, François Rivier1,2, Gaëlle de Barry3
1Département de Neuropédiatrie, CHU de Montpellier, Montpellier, France.
Developmental medicine and child neurology
|January 24, 2024
概括
这项研究发现,在接受不同初始剂量静脉克罗纳泽 (CLZ) 治疗的状态 (CSE) 的儿童中,停止率没有显著差异. 然而,较低的CLZ剂量需要更频繁的第二剂量.
科学领域:
- 儿科神经学 儿科神经学
- 紧急医疗 紧急医疗
背景情况:
- 状态 (CSE) 是儿童的一种医疗紧急情况.
- 静脉注射的二类药物,如克罗纳泽帕姆 (CLZ),是CSE的第一线治疗.
- 儿科CSE中CLZ的最佳剂量策略需要进一步研究.
研究的目的:
- 为了比较静脉注射克罗纳泽巴姆 (CLZ) 在儿童性状态 (CSE) 的初始管理中的疗效.
- 评估一线住院剂量CLZ对停止率和需要额外剂量的影响.
主要方法:
- 在蒙彼利埃大学医院进行了一项单心回顾性研究.
- 包括2016年1月至2019年6月期间用CLZ治疗CSE的儿童.
- 对临床表现,治疗和结局的数据是根据最初的CLZ剂量进行分析的.
主要成果:
- 在接受CSE治疗的105名儿童中,有24名儿童接受低剂量 (<0.03毫克/公斤),69名儿童接受高剂量 (≥0.03毫克/公斤).
- 在低剂量 (62.5%) 和高剂量 (76%) 组之间,停止率没有显著差异 (p=0.29).
- 在低剂量组中,第二剂CLZ的频率明显高 (37.5%对16%,p=0.04).
结论:
- 静脉注射克洛纳泽的初始剂量没有显著影响儿科CSE的终止率.
- 较低的CLZ初始剂量 (<0.03 mg/kg) 与需要第二剂量的可能性更高有关.
- 这些发现表明,虽然初始疗效可能相似,但剂量选择可能会影响治疗持续时间和随后干预的需要.
更多相关视频
04:51Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
Published on: April 11, 2019
9.4K
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
20.3K
相关概念视频
01:20Antiepileptic Drugs: Potassium Channel Activators
183
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
183
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
303
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
303
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
403
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
403
01:17Antiepileptic Drugs: Calcium Channel Blockers
403
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
403
01:13Seizures: Classification
362
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
362
01:24Parenteral Anesthetics: Overview
127
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
127